Search clinical trials for: Fluarix™/Influsplit SSW® 2007/2008

Total 203 results

GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People 18 Years Old or Above

Influenza

Germany
GlaxoSmithKline

Completed

Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03

Influenza

Germany
GlaxoSmithKline

Completed

Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04

Influenza

Germany
GlaxoSmithKline

Completed

Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years

Influenza

Germany
GlaxoSmithKline

Completed

A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults

Influenza

Germany
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

Influenza

Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older

Influenza

Germany
GlaxoSmithKline

Completed

A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in Adults

Influenza

Germany
GlaxoSmithKline

Completed

A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above

Influenza

Germany
GlaxoSmithKline

Terminated

Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM

Influenza

Germany
GlaxoSmithKline

Completed

Annual Study for Fluarix Registration

Influenza

Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

Influenza

Korea, Republic of
Sanofi

Completed

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

Influenza | Myxovirus Infection | Orthomyxoviruses

United States
GlaxoSmithKline

Completed

Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over

Influenza

Norway, Estonia, Denmark
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children

Influenza

United States, Germany, Poland, Spain, Czechia, Bangladesh, France
Sanofi Pasteur, a Sanofi Company

Completed

Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older

Influenza

Germany
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations

Completed

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana

Lassa Fever

Ghana
Sanofi Pasteur, a Sanofi Company

Completed

Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine

Influenza

United States
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations

Completed

Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers

Lassa Fever

United States
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above

Influenza

Brazil
Boston Scientific Corporation
ICON plc

Completed

Maximizing CRT Delivery by Using MultipolAr Coronary Sinus Lead FamiLy ACUITY® X4 - RALLY X4 Study (RallyX4)

Heartfailure

Spain, Belgium, Netherlands, Hong Kong, Italy, France, Finland, Switzerland, Israel, Germany, United Kingdom, Colombia, Singapore, Denmark, Portugal, Japan, Austria, Ireland
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Influenza Virus Vaccines in Children and Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine

Influenza

United States
GlaxoSmithKline

Completed

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older

Influenza

Belgium, France
Sanofi Pasteur, a Sanofi Company

Completed

Study of Safety and Immunogenicity of Fluzone® in Healthy Children

Influenza

United States
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations

Completed

Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers

Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Lebanon, Jordan, Kenya
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Duke University

Completed

Assessment of InfraScanner 2000™ in Detecting Subdural and Epidural Hematomas

Head Injuries, Closed | Head Trauma | Head Injuries | Craniocerebral Injuries | Crushing Skull Injury | Head Injuries, Multiple | Head Trauma,Closed | Head Trauma Injury | Head Trauma, Penetrating | Head Injury, Minor | Head Injury Major | Head Injury, Open | Injuries, Craniocerebral | Injuries, Head | Multiple Head... and other conditions

United States, Uganda
Sanofi Pasteur, a Sanofi Company

Completed

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

Influenza

United States
Merck Sharp & Dohme LLC

Withdrawn

A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)

Varicella
Duke University

Completed

Assessment of InfraScanner 2000™ in Detecting Subdural and Epidural Hematomas

Head Injuries, Closed | Head Trauma | Head Injuries | Craniocerebral Injuries | Crushing Skull Injury | Head Injuries, Multiple | Head Trauma,Closed | Head Trauma Injury | Head Trauma, Penetrating | Head Injury, Minor | Head Injury Major | Head Injury, Open | Injuries, Craniocerebral | Injuries, Head | Multiple Head... and other conditions

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

Influenza

United States
University of Sao Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Dental Anesthesia in Pregnant Women With Rheumatic Heart Disease

Pregnancy | Dental Caries | Rheumatic Heart Disease

Brazil
Inovio Pharmaceuticals

Completed

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

Respiratory Papillomatosis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Herpes Zoster

Germany, Canada, United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly

Influenza

Sweden
Derming SRL

Completed

Aesthetic Performance of an Intradermal Injection Treatment for Face Photoaging: Interstitial or Cushion Technique in Comparison to Bolus Technique at Five Points (Half - Face Method Within Subjects)

Face Photoaging

Italy
Merck Sharp & Dohme LLC

Completed

Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)

Varicella
Inovio Pharmaceuticals
Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.

Terminated

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Infection | COVID-19 Disease

United States, Mexico, Colombia
Centre d'Investigation Clinique et Technologique...
Adep Assistance

Completed

Instrumental and Manual Increase of Couch in Neuromuscular Patients (OPTICOUGH)

Chronic Respiratory Failure | Neuromuscular Disease | Coughing

France
Derming SRL

Completed

Efficacy and Tolerance Evaluation of an Injective Treatment for the Area Around the Eyes

Under-eyes Dark Circles

Italy
Novartis Pharmaceuticals

Recruiting

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Non-Small Cell Lung Carcinoma

India
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)

Measles | Rubella | Mumps | Varicella
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations

Completed

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers

Coronavirus Infection

United States
Xequel Bio, Inc.
United States Department of Defense

Withdrawn

Study of the Efficacy and Safety of Granexin® Gel to Improve Burn Wound Healing

Thermal Burn | Second Degree Burn
University Hospital, Clermont-Ferrand

Recruiting

Cardiovascular Risk in Digital Osteoarthritis (RICARDI)

Lumbago | Osteoporosis | Radiculopathy Lumbar | Osteoarthritis Hand

France
Acuity Polymers, Inc.

Not yet recruiting

Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear (Acuity200OK)

Myopia

United States, Australia, New Zealand

3

Subscribe